Iscador® P (Mistletoe) Immunotherapy for Recurrent Resectable Osteogenic Sarcoma

This will be a phase II, single arm study of osteosarcoma patients with fully resected pulmonary metastases. The MTD corresponds to the dosage recommendations of the manufacturer of Iscador® P which is licensed in Sweden, New Zealand, South Korea, Germany and Switzerland for the treatment of solid tumors and precancerous lesions. The study population includes patients with relapse of osteosarcoma in the lung following surgical resection of all gross disease (2nd or greater CR). Following completion of final thoracotomy, they will be treated with Iscador® P at concentrations up to the MTD with surveillance imaging via CT scan to monitor for relapsed disease.

NCT Number	NCT05726383
Lead Sponsor	Hackensack Meridian Health Collaborators: M.D. Anderson Cancer Center, Iscador AG, Arlesheim, Switzerland., Tackle Kids Cancer, Susan Zabransky Hughes Foundation
Conditions	Osteogenic Sarcoma Recurrent
Enrollment	32 participants
Start Date	2024-05-14
Primary Completion	2027-05-11 (estimated)
Study Completion	2027-05-11 (estimated)
Updated on ClinicalTrials.gov	2026-05-22